19–008

108TH CONGRESS REPORT " HOUSE OF REPRESENTATIVES ! 1st Session 108–231

PROVIDING FOR CONSIDERATION OF H.R. 2427, 

PHARMACEUTICAL MARKET ACCESS ACT OF 2003

JULY 24 (legislative day of JULY 23), 2003.—Referred to the House Calendar and 

ordered to be printed 

Mr. SESSIONS, from the Committee on Rules, 

submitted the following 

R E P O R T 

[To accompany H. Res. 335] 

The Committee on Rules, having had under consideration House 

Resolution 335, by a nonrecord vote, report the same to the House 

with the recommendation that the resolution be adopted. 

SUMMARY OF PROVISIONS OF THE RESOLUTION

The resolution provides for consideration in the House of H.R. 

2427, the Pharmaceutical Market Access Act of 2003, under a 

closed rule. The rule provides one hour of debate equally divided 

and controlled by the chairman and ranking minority member of 

the Committee on Energy and Commerce, or their designees. The 

rule waives all points of order against consideration of the bill and 

provides one motion to recommit. 

The rule further provides that during consideration of the bill, 

notwithstanding the operation of the previous question, the Chair 

may postpone further consideration of the bill to a time designated 

by the Speaker. 

COMMITTEE VOTES

Pursuant to clause 3(b) of House rule XIII the results of each 

record vote on an amendment or motion to report, together with 

the names of those voting for and against, are printed below: 

Rules Committee record vote No. 178

Date: July 23, 2003. 

Measure: H.R. 2427, Pharmaceutical Market Access Act of 2003. 

Motion by: Mr. Frost. 

Summary of motion: To make in order and provide the appropriate waivers for the amendment offered by Representative EmerVerDate Jan 31 2003 07:28 Jul 24, 2003 Jkt 019008 PO 00000 Frm 00001 Fmt 6659 Sfmt 6602 E:\HR\OC\HR231.XXX HR231
2

son which allows the Secretary of HHS to create a Canada-only 

demonstration project wherein pharmacists and wholesalers could 

‘‘re-import’’ FDA-approved prescription medications manufactured 

in FDA-approved facilities back into the U.S. 

Results: Defeated 4 to 8. 

Vote by Members: Goss—Nay; Linder—Nay; Pryce—Nay; DiazBalart—Nay; Myrick—Nay; Sessions—Nay; Reynolds—Nay; 

Frost—Yea; Slaughter—Yea; McGovern—Yea; Hastings (FL)—Yea; 

Dreier—Nay.

Rules Committee record vote No. 179

Date: July 23, 2003. 

Measure: H.R. 2427, Pharmaceutical Market Access Act of 2003. 

Motion by: Mrs. Slaughter. 

Summary of motion: To report an open rule. 

Results: Defeated 4 to 8. 

Vote by Members: Goss—Nay; Linder—Nay; Pryce—Nay; DiazBalart—Nay; Myrick—Nay; Sessions—Nay; Reynolds—Nay; 

Frost—Yea; Slaughter—Yea; McGovern—Yea; Hastings (FL)—Yea; 

Dreier—Nay. 

Rules Committee record vote No. 180

Date: July 23, 2003. 

Measure: H.R. 2427, Pharmaceutical Market Access Act of 2003. 

Motion by: Mr. McGovern. 

Summary of motion: To increase the amount of general debate 

time to four hours. 

Results: Defeated 4 to 8. 

Vote by Members: Goss—Nay; Linder—Nay; Pryce—Nay; DiazBalart—Nay; Myrick—Nay; Sessions—Nay; Reynolds—Nay; 

Frost—Yea; Slaughter—Yea; McGovern—Yea; Hastings (FL)—Yea; 

Dreier—Nay. 

Rules Committee record vote No. 181

Date: July 23, 2003. 

Measure: H.R. 2427, Pharmaceutical Market Access Act of 2003. 

Motion by: Mr. Hastings of Florida. 

Summary of motion: To make in order and provide the appropriate waivers for the amendment offered by Representative 

Deutsch which requires the FDA to place one FDA official per 

200,000 shipments (annual) of pharmaceuticals exported from 

wholesale/distributor warehouses to the U.S. These FDA officials 

will be required to keep records of daily, weekly, and monthly averages regarding type and quantity of drugs to be re-imported into 

the U.S. 

Results: Defeated 4 to 8. 

Vote by Members: Goss—Nay; Linder—Nay; Pryce—Nay; DiazBalart—Nay; Myrick—Nay; Sessions—Nay; Reynolds—Nay; 

Frost—Yea; Slaughter—Yea; McGovern—Yea; Hastings (FL)—Yea; 

Dreier—Nay.

Æ